Posted by Michael Wonder on 01 Apr 2020
Breakthrough medicines now available for blood cancer, breast cancer, HIV and epilepsy, saving patients up to $194,000
1 April 2020 - There’s new hope for thousands of Australian patients with myeloma, breast cancer, HIV and epilepsy, with the Australian Government expanding the listing of four key medicines on the Pharmaceutical Benefits Scheme.
From 1 April, Revlimid (lenalidomide) will be available to patients receiving maintenance treatment for newly diagnosed multiple myeloma, who have already undergone an autologous stem cell transplant.
The PBS listing of Kadcyla (trastuzumab emtansine) has been expanded to include the treatment of patients with HER-2 positive early breast cancer following surgery.
